

Albert E Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8310698/publications.pdf>

Version: 2024-02-01

15
papers

255
citations

1307594

7
h-index

1474206

9
g-index

17
all docs

17
docs citations

17
times ranked

218
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. <i>Nature Communications</i> , 2022, 13, 1325.	12.8	31
2	Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. <i>Cancer Immunology Research</i> , 2022, 10, 996-1012.	3.4	18
3	Abstract PO-026: Convolutional neural network assessment of immune activation state of brain metastases. , 2021, , .		0
4	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. <i>Nature Cancer</i> , 2021, 2, 498-502.	13.2	26
5	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. <i>Neuro-Oncology Practice</i> , 2021, 8, 662-673.	1.6	6
6	Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid. <i>JAMA Network Open</i> , 2021, 4, e2120040.	5.9	27
7	Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. <i>Nature Communications</i> , 2021, 12, 5954.	12.8	35
8	Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. <i>Nature Communications</i> , 2021, 12, 5955.	12.8	25
9	IMMU-02. GENOMIC AND TRANSCRIPTOMIC CORRELATES OF IMMUNOTHERAPY RESPONSE WITHIN THE TUMOR MICROENVIRONMENT OF LEPTOMENINGEAL METASTASES. <i>Neuro-Oncology</i> , 2021, 23, vi92-vi92.	1.2	0
10	CTIM-30. PHASE II TRIAL OF PEMBROLIZUMAB IN RECURRENT AND RESIDUAL HIGH-GRADE MENINGIOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi57-vi57.	1.2	0
11	QOLP-01. EXPERIENCES FROM PATIENT, CAREGIVER, AND PHYSICIAN SURVEYS ON DIAGNOSIS AND TREATMENT OF BRAIN METASTASES. <i>Neuro-Oncology</i> , 2021, 23, vi182-vi182.	1.2	0
12	BIOM-04. SENSITIVE DETECTION OF LEPTOMENINGEAL DISEASE USING CELL-FREE DNA FROM CEREBROSPINAL FLUID. <i>Neuro-Oncology</i> , 2021, 23, vi10-vi10.	1.2	0
13	CTIM-02. PHASE II STUDY OF IPILIMUMAB AND NIVOLUMAB IN LEPTOMENINGEAL CARCINOMATOSIS. <i>Neuro-Oncology</i> , 2021, 23, vi49-vi49.	1.2	0
14	Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. <i>Nature Medicine</i> , 2020, 26, 1280-1284.	30.7	83
15	NIMG-05. ADVANCED IMAGING TO ASSESS LONGITUDINAL VASCULAR CHANGES IN BRAIN METASTASES TREATED WITH CHECKPOINT INHIBITION. <i>Neuro-Oncology</i> , 2020, 22, ii147-ii147.	1.2	0